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Atherothrombosis, which directly threatens people’s health and lives, is the main cause of morbidity and mortality all over the
world. Platelets play a key role in the development of acute coronary syndromes (ACSs) and contribute to cardiovascular events.
Oral antiplatelet drugs are a milestone in the therapy of cardiovascular atherothrombotic diseases. In recent years, many reports
have shown the possibility that “resistance” to oral anti-platelet drugs and many adverse reactions, such as serious bleeding risk,
which provides an impetus for developing new anti-platelet drugs possesses highly eﬃciency and fewer adverse eﬀects. Study
on the blood stasis syndrome and promoting blood circulation and removing blood stasis is the most active ﬁeld of research of
integration of traditional and western medicine in China. Blood-stasis syndrome and platelet activation have close relationship,
many Chinese herb and formulas for promoting blood circulation and removing blood stasis possess deﬁnite anti-platelet eﬀect.
This paper covers the progress of anti-platelet mechanism of Chinese herb and formulas for promoting blood circulation and
removing blood stasis and is to be deeply discussed in further research.
1.Introduction
Cardiovascular and cerebrovascular events have become the
major killer of people’s health and life all over the world.
Rupture of atherosclerotic plaque in an artery wall and the
ensuing thrombotic events are the triggers for acute ischemic
injury. Activated platelets play a pivotal role in the formation
of pathogenic thrombi underlying acute clinical manifesta-
tions of vascular atherothrombotic disease. Oral antiplatelet
drugsareamilestoneinthetherapyofcardiovascularathero-
thrombotic diseases and provide the primary and secondary
prevention strategy to combat these diseases. Eﬃcient
antiplatelet therapy can make the death rates of heart disease
and stroke decline by about 25% [1, 2]. Commonly used oral
antiplatelet drugs include cyclooxygenase inhibitor aspirin,
the glycoprotein IIb/IIIa inhibitor ReoPro, and the P2Y12
inhibitor clopidogrel, et al. Many clinical studies show that
dual antiplatelet therapy with aspirin and clopidogrel is
currently the standard of drugs for prevention of adverse
cardiovascular events in most patients at high risk owing to
acute coronary syndromes or recent placement of a stent.
But along with prolonging of treatment by dual or
triple antiplatelet drugs, the eﬀectiveness and security have
garnered particular attention in clinic. Despite their proven
beneﬁt, recurrent cardiovascular events still occur in those
taking antiplatelet drugs. This has led to the concept of
antiplatelet resistance [3], most commonly aspirin resistance
as this drug is the cornerstone of most regimens. Although
there are some debates on deﬁnition and mechanism of
antiplatelet resistance [4, 5], it cannot be denied that it has
important clinical signiﬁcance. At the same time, numerous
adverse reactions including serious bleeding risk (digestive
and nervous systems) and combination with PPIs and statin
[6, 7], which limit the clinical practice of antiplatelet drugs.
So developed novel classes of antiplatelet agents possess high
eﬃciency, and fewer adverse eﬀects have been always the
researchfocusforpreventionofcardiovasculardisease.Mod-
ern medicine and pharmacology has done a lot of valuable
exploration, newer agents are in development recent years
that include prasugrel, cangrelor, ticagrelor, and vorapaxar,
et al. [8].
Study on the blood stasis syndrome (BSS) and promoting
blood circulation and removing blood stasis (PBCRBS) is the
most active ﬁeld of research of integration of traditional and
western medicine in China. During the past 50 years, much2 Evidence-Based Complementary and Alternative Medicine
Table 1: The ingredient of frequently used formulas for promoting blood circulation and removing blood stasis.
Names of formulas Ingredients of formulas Label
Xiongshao capsule Szechuan Lovage Rhizome, Red Paeony Root Chinese patent drug
Compound danshen
dripping pills The root of red-rooted salvia, Panax notoginseng, Borneol Chinese patent drug
Buyanghuanwu decoction Radix Astragali Bunge, Peach Seed, Saﬄower, Szechuan Lovage Rhizome, Angelica
sinensis, Red Paeony Root, earthworm
Xuesaitong capsule Panax Notoginsenosides Chinese patent drug
Tongxinluo capsule Sanguisuge, Scorpio, centipede, ground beeltle, cicada slough, et al. Chinese patent drug
Danhong injection The root of red-rooted salvia, saﬄower Chinese patent drug
Taohongsiwu decoction Peach Seed, Saﬄower, Szechuan Lovage Rhizome, Angelica sinensis, white paeony root,
Radix Rehmanniae Praeparata
Xue Fu Zhu Yu decoction
hovenia dulcis, radix achyranthis bidentatae, peach seed, saﬄower, Szechuan Lovage
Rhizome, Angelica sinensis, white paeony root, Radix Rehmanniae Praeparata, radix
bupleuri, Platycodon grandiﬂorum, et al.
signiﬁcant progress has been made from theory, experiments
to clinic ﬁelds based on the inherit, and innovation of
thoughts in traditional Chinese medicine [9], to clarify the
treatment regulations and principles of PBCRBS, which has
already got consensus in medical community in China. A
lot of formulas for PBCRBS (see Table 1) have showed great
antiplatelet eﬀect in clinic, and most of them are the Chi-
nese patent drugs. On the prevention of atherosclerosis or
vulnerable plaque, Chinese and Western medicine have the
consensus that stabling plaque and promoting blood circula-
tion. Based on the agreed thoughts of the Eastern and West-
ern worlds, the application of Chinese herb and formulas
for PBCRBS has valuable signiﬁcance in the exploration of
reducing the risk of cardiovascular event [10].
Blood-stasis syndrome has the status of platelet activa-
tion, and it has high correlation [11, 12]. As early as the
lastcenturyof1970s,therewerescholarswhohadmadepilot
study to observe the mechanism of Chinese herb and formu-
lasforPBCRBSonplateletfunction[13].BSShasthedeﬁnite
diagnostic criteria [14] from 1991 in China, and during the
past 5 years, diagnosis criteria have improved by scholars
[15] and keep pace with the development of TCM. There is
a special focus on natural compounds present in dietary and
medicinal plants exhibiting antiplatelet/thrombotic proper-
ties. Now we know that platelet mainly was regulated by
three kinds of substance, one kind is generated out of plate-
let such as catecholamine, collagen, thrombin, and prosta-
cyclin; the second kind is generated from platelet and acts
on the platelet membrane glycoproteins such as ADP, PGD2,
PGE2, and 5-HT; the last kind is generated from platelet and
acts on the platelet such as TXA2, cAMP, cGMP, and Ca2+,
et al. Some of these substances have been identiﬁed as
eﬀective target of antiplatelet. Owing to the many problems
of eﬀectiveness and security of current antiplatelet drugs, a
great need now arises to develop both eﬃcacious and phar-
maceutical medicines to combat these diseases. Screening
the highly eﬃciency and fewer adverse eﬀects of antiplatelet
drugs from Chinese herb and formulas for PBCRBS attracts
great attention of researchers, and the study of target or
mechanism of Chinese herb and formulas for PBCRBS to
be the hot topic of research and development of antiplatelet
drugs. It had been approved that antiplatelet mechanism of
Chinese herb and formulas for PBCRBS involves the follow-
ing aspects.
2. AntiplateletMechanismof ChineseHerband
Formulas of Promoting Blood Circulation
andRemoving Blood Stasis
2.1. Inhibition of Platelet Aggregation. Platelet aggregation
means the clumping together of platelets in the blood, which
is the main function of platelet and has key role in the
physiological hemostasia and pathogenesis of atherothrom-
bosis. Platelet activates when it adheres to breakage of
vessel or has been induced by activator. Activated platelet
membrane glycoprotein (GP) IIb/IIIa exposes its ﬁbrinogen
receptor with the participation of Ca2+, one ﬁbrinogen can
bind to at least two GP IIb/IIIa at the same time, and
platelet clump together with ﬁbrinogen by GP IIb/IIIa. The
typical aggregation is induced by diﬀerent activators, which
included the following two aspects, one is chemical agents
such as ADP, collagen, thrombin, AA, and PAF, et al.; the
other is shear stress. It is now taken that platelet aggregation
rate (PAR) is the evaluation criterion of the intensity. Born
[16]designedtheplateletaggregationanalyzerin1962bythe
turbidimetryprinciplewhichtoacceleratetheunderstanding
of platelet aggregation. Now PAR was considered as the
marker of antiplatelet eﬃcacy evaluation and was used
intensively in medical research of platelet. Studies show that
the vast majority of Chinese herb and formulas for PBCRBS
suchasXiongshaoCapsule[17],CompoundDanshendripping
pills [18], Buyanghuanwu Decoction [19], Xuesaitong Capsule
[20],DaH uangZheChongpill[21],andTongxingluoCapsule
[22], et al. can reduce the PAR of patients or animal model
of thromboembolic diseases signiﬁcantly. Active principles
such as ferulic acid [23], ligustrazine [24], propyl gallate [25],
resveratrol [26],curdione [27],TotalﬂavoneinSanguisDraco-
nis [28], Salvianolic acid B [29], Hirulog [30], and Saﬄower
ﬂavin [31] et al. can inhibit the platelet aggregation induced
by AA, ADP, PAF, collagen, and thrombin to some extent,
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2.2. Inhibition of Platelet Release Reaction. Platelet release
reaction means that many substances stored in α-granules,
dense granule, and lysosome in platelet are released out of
platelet upon diﬀerent activator. These substances including
CD62p(P-selection),GPIIb/IIIacompound,PKC,β-TG,PF-
4, and Ca2+, which has been considered as the usual eval-
uation indicator of screening the eﬀective antiplatelet drug
from Chinese herb and formulas for PBCRBS.
2.2.1. CD62P. CD62p (P-selection) is a 140 kD glycoprotein
which is present in the granules of platelets and translocates
rapidly to the cell surface after platelet activation and is
generally considered to be the gold marker of platelet acti-
vation[32,33].Clinicalresearchindicatesthattheexpression
of CD62p increases markedly in the diﬀerent types of
cardiovascular patients (including patients with stable angi-
naandACS)[34–36]andhasfoundhighpositive correlation
between CD62p level and blood stasis syndrome (BSS)
[37]. So making the increased expression of CD62p after
platelet activation dropped is taken for the one of the
antiplatelet mechanisms and scientiﬁc measurements of
Chinese herb and formulas for PBCRBS. According to the
currentstudies,Danhonginjection[38],Ligustrazineinjection
[39], Compound Danshen dripping pills [40], Taohongsiwu
Decoction [41], and Tongxinluo capsule [42] can reduce the
CD62p expression after platelet activation signiﬁcantly and
inhibit platelet activation in vivo, to show satisfactory eﬀect
of antiplatelet.
2.2.2.GPIIb/IIIaCompound. ThedetectionofPAC-1iscon-
sideredasthesensitiveandimportantmarkerofplateletacti-
vation [43], PAC-1 is the speciﬁc monoclonal IgMK, which
only binds to activating platelet GPIIb/IIIa compound, while
it has no recognition capability for resting one. The activa-
tion of GPIIb/IIIa depends on the platelet activation which
makes the former change its conﬁguration to have strong
aﬃnity with receptors. Using the ﬂow cytometry to detect
PAC-1 which has the characteristic of speciﬁc fast sensitive,
and has splendid future in the study on screening antiplatelet
drugs from Chinese herb and formulas for PBCRBS.
Da Huang Zhe Chong pill is the earliest formula of
PBCRBS and is widely used for atherothrombotic disease
treatment. Research shows that it has better antiplatelet
aggregation ability than aspirin [44], the further study
indicates that it can reduce the level of PAC-1 after ADP-
induced platelet activation and of patients with coronary
heart disease and cerebral infarction in clinic, which also has
superior antiplatelet activation than aspirin [21] and is an
ideal antithrombotic drug. Other study [45] found that Xue
F uZ h uY ud e c o c t i o ncan inhibit the ADP-induced expression
of GPIIb/IIIa compound signiﬁcantly and restrain the ADP-
induced platelet activation, which provides experimental
evidence to long-term treatment of coronary heart disease,
and no symptoms of myocardial ischemia, et al.
2.2.3. PKC. protein kinase C (PKC), a ubiquitous protein
kinase found in a variety of animal tissues, has been impli-
cated in the regulation of many cellular processes and plays
a central role in signal transduction. In platelets, the PKC
is an important signaling mediator required for activation,
secretion of granule contents, and aggregation [46]. During
the process of platelet activation, close relationship between
translocation of PKC in platelet and platelet function has
been found. PKC has both cytosolic and plasma membrane-
bound forms, and the former is the most abundant under
resting conditions. The cytosolic form can translocate to the
plasma membrane upon cell stimulation and elevation of
cellular Ca2+, one particular and important aspect of PKC
activation is the intracellular redistribution of the enzyme
from the cytosol to the cell membrane [44]. Now translo-
cation or redistribution of PKC from the cytosolic form to
the plasma membrane can be taken for an indicator of PKC
activation [47].
Resveratrol (RESV), a well-known polyphenolic com-
pound of, was extracted from Polygonum Cuspidatum,w h i c h
was a Chinese herb for PBCRBS and has been eﬃcaciously
usedintraditional Chinese medicine totreatseveraldiseases,
including thromboembolic diseases for over hundreds of
years. In recent years, pharmacological studies have found
that RESV possesses multifaceted cardiovascular beneﬁts,
but the mechanism is not clear. Recent research [48] shows
that PKC distributed mostly across the cytosol of platelets
in resting platelets and redistributed to the membrane later
to be activated by ADP. If pretreated by RESV,P K Ct r a n s -
location to the membrane was partially inhibited in the
platelets activated by ADP. These results suggested that RESV
inhibited the PKC-mediated signal transduction pathway in
platelets, and it might act as an inhibitor on PKC activity in
platelets and serve as a novel antithrombotic agent.
2.2.4. PF-4 and β-TG. It is thought that PF-4 and β-TG are
the speciﬁc indicators of platelet release reaction [49]. Both
increases of PF-4 and β-TG indicate the height of platelet
release reaction, which is common in thromboembolic dis-
ease and prethrombotic state. On the contrary, both
decreasesofPF-4andβ-TGindicatethesuppressionofplate-
let release reaction. β-TG can make the PGI2 concentration
and adenylate cyclase activity reduction, and then make
cAMP decrease which bring about weak inhibition and en-
hance the aggregation of platelet [50, 51]. PF-4 can reduce
the anticoagulation of heparan sulphate in endothelial cell
and enhance the metabolism of membrane phospholipid
and AA, to produce TXA2, also PF-4 can promote precipi-
tation and polymerization of ﬁbrin monomer and accelerate
platelet aggregation [52]. Research has found that Salvia
miltiorrhiza Bunge injection [53] can reduce the PF-4 and β-
TG concentration markedly to inhibit platelet aggregation.
2.2.5.Ca2+. Calciumionplaysavitalroleinthedevelopment
of platelet activation. The transformation, aggregation, and
release reaction of platelet are triggered by the increase of
free calcium ion concentration of platelet ([Ca2+]i), which
is the essential mechanism of thrombosis [54]. Studies have
found that the increase of [Ca2+]i in patient with CHD,
meanwhile calcium antagonist can reduce [Ca2+]i of platelet
accompanied by inhibiting platelet aggregation [55].4 Evidence-Based Complementary and Alternative Medicine
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Studies [56] have indicated that some Chinese herbs,
such as Salvia Miltiorrhiza, Ligusticum wallichii Franch,
Carthamus tinctorius, Radix Paeoniae Rubra, and some active
constituents as Ligustrazine (see Figure 1), Tanshinone IIA
(see Figure 2), et al. have the certain eﬀect of calcium chan-
nel antagonists and have good results of inhibit platelet
aggregation and activation. Another research [57] shows that
Saﬄor yellow (a kind of soluble natural pigment of Car-
thamus tinctorius) can inhibit platelet release of 5-HT and
Ca2+, which has similar eﬀect to Ginkgolides (admitted PAF
receptor antagonist), which means that Saﬄor yellow might
suppress the platelet activation via inhibition of PAF and
calcium inﬂux.
2.3. Inﬂuence of the Process of Platelet Metabolism
2.3.1. Inﬂuence of the Metabolic System of Arachidonic Acid
(AA). TXA2 and PGI2 are the metabolites of AA, which
have the strong bioactivity of PG, and have a short half-
life, quickly degrad to the TXB2 and 6-keto-PGF1α, the latter
make further metabolizes to the 6-keto-PGE.
It is now thought that many cardiovascular diseases such
as atherosclerosis, thrombosis, coronary spasm, acute myo-
cardial infarction, and hypertension have close relationship
with the disequilibrium of TXA2/PGI2 [58]. TXA2,w h i c hi s
synthesized and released by platelet microsome and has the
function of promoting platelet aggregation and thrombosis,
is one of the strong inducers of platelet aggregation and
vasoconstrictor. TXA2 promotes the Ca2+ of density tube
system free to make dense bodies contracting and releasing
ADP and 5-HT, which result in platelet aggregation. PGI2
is the main metabolite of AA and is the strong endogenous
inhibitor of platelet aggregation; it has the function of
antiplatelet aggregation and vasorelaxant and is considered
asthevascularprotectionfactor.Undernormalphysiological
state, TXA2 and PGI2 have the balance condition and keep
the platelet internal environment stable. Out of balance of
TXA2 and PGI2 in plasma or tissue is one of the reasons
of platelet aggregation, vasospasm, and thrombosis. Studies
show that inﬂuence of TXA2/PGI2 has been closely related
to antiplatelet mechanism of Chinese herb and formulas for
PBCRBS, such as Total saponins of paeonia [59]c a nr e d u c e
the ADP-induced platelet maximum aggregation rate and
plasma TXB2 concentration, meanwhile, increase the plasma
6-keto-PGF1α concentration, which means it can promote
thereleaseofPGI2,inhibit theproduceofTXA2,improvethe
balance of TXA2/PGI2, and reach the aim of antithrombotic
therapy. The same results have been found in the following
drugs: Guanxin II [60], Taohongsiwu Decoction [61], Noto-
ginsenoside [62], salvianolic acid A [63], Honghua injection
[64], et al.
2.3.2. Inﬂuence of the Metabolic System of cAMP and cGMP.
cAMP and cGMP in platelet are the second messengers
of signal transmission, which make the diﬀerent platelet
activators acting on the speciﬁc receptor, then resulting in
platelet aggregation and activation. Studies [65, 66] show
that drugs which make the level of cAMP and cGMP increase
can inhibit platelet aggregation owing to promoting the
intake of calcium ions, lowering the level of Ca2+, and having
close relation with the phosphorylation of myglobulin. So
whether can aﬀect the metabolic system of cAMP and cGMP
has been taken as the main point of antiplatelet mechanism
of Chinese herb and formulas for PBCRBS. Research [19]
shows that BuYangHuanWu decoction can inhibit the ADP-
induced platelet aggregation and the decrease of cAMP and
cGMP after the platelet aggregation, which suggested that
its antiplatelet aggregation may be related to inhibiting the
decreaseofcyclicnucleotideinplateletsaftertheaggregation.
Compound Danshen dripping pills [67]a n dpseudoginseng
[68] have the same mechanism of antiplatelet.
2.4. Inﬂuence of the Signal Transduction in Platelet. There is a
seriesofsignaltransductionsinplatelet,whichhascloserela-
tionship with platelet activation. Upon agonist stimulation,
speciﬁc receptor of membrane binds to the ligand to make
the conformational changes and to activate the key enzymes
action, which produces or releases the signal molecules and
led to adhesion, aggregation, and reaction release to form
thrombus at last. The mechanism of transmembrane signal
transduction in platelet is unclear owing to more than one
receptor bound by platelet agonist and the activated platelet
release α-granules as secondary agonist to bring about am-
pliﬁcation eﬀect [69]. Platelet signal transduction pathway
usually includes several aspects [70]: PI3-K pathway, PLC-β
pathway, PTK pathway, MARK pathway, cAMP-PKA path-
way, and PLA2 pathway. At present, most researches are
about Phosphoinositide 3-kinase (PI3K). PI3K is a critical
transmitter of intracellular signaling during platelet activa-
tion. The PI3K family is divided into three classes (I, II, and
III). Depending on diﬀerences in the heterodimerization of
catalytic subunits and regulatory subunits, class I is furtherEvidence-Based Complementary and Alternative Medicine 5
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divided into IA (PI3Kα,P I 3 K β,a n dP I 3 K γ) and IB (PI3Kδ),
PI3Kβ and PI3Kγ are crucial in platelet signaling [71]. Akt
phosphorylationcanbeusedasanindicatorofPI3Kpathway
activation [72, 73].
In recent years, with the further study of antiplatelet
mechanism of Chinese herb and formulas for PBCRBS,
there are studies involving signal transduction in platelet to
investigatethemechanism.SalvianolicacidA(SAA,Figure 3)
is a water-soluble component from the root of Salvia miltior-
rhiza Bunge, a herb that is widely used for atherothrombotic
disease treatment in China. New study [74] shows that SAA
could inhibit platelet spreading on ﬁbrinogen, a process
mediated by outside-in signaling. Western blot analysis
showed that SAA, like the PI3K inhibitors LY294002 and
TGX-221, potently inhibited PI3K, as shown by reduced akt
phosphorylation, which indicates that the target spot may
be the PI3Kβ.T h ein vitro ﬁndings were further evaluated
in the mouse model of arterial thrombosis, in which SAA
prolongedthemesentericarterialocclusiontimeinwild-type
mice. Interestingly, SAA couldeven counteractthe shortened
arterialocclusiontimeinLdlrtmlHer mutantmice.Andforthe
ﬁrst deﬁned the fact [74] that SAA inhibits platelet activation
via the inhibition of PI3K and attenuates arterial thrombus
formation in vivo. The results suggest that SAA may be
developed as a novel therapeutic agent for the prevention of
thrombotic disorders.
3. DiscussionandPerspective
From above mentioned, during the past 30 years, research
of antiplatelet and antithrombotic therapy of Chinese herb
andformulasforPBCRBShasmaderapidprogress,butthere
are still some problems existing. In the clinical research, at
present many studies limited to small sample of curative
eﬀects, lack of multicenter, prospective, large sample, and
control study which made the clinical practice of Chinese
herb and formulas for PBCRBS be short of deﬁnite clinical
evidence. And Chinese scholars has begun to attempt to
study like above and got to some good results [75]. But those
which deserve attention are, in the practical use of clinical
medicine, we should comply with the principle of diﬀer-
entiation of symptoms and signs, minimize the potential
abuse, and improve on the clinical practical eﬀects. In the
experimental research, many studies mainly focused on the
mechanism on one aspect of a certain Chinese herb and
formulas for PBCRBS, the experimental design owes rigor,
and only a few studies were equipped with in vitro and in
vivo at the same design. It is generally known that platelet
activation is a complex, multifactor process, which involves
adhesion, aggregation, and reaction release, for example,
there are diﬀerent platelet activation stimulators, which have
the diﬀerent mechanism of platelet aggregation and signal
transduction, it is necessary to take a systematic study on
the mechanism of Chinese herb and formulas for PBCRBS
inhibiting platelet aggregation by diﬀerent stimulators in the
future and making further study on the signal transduction
in platelet, now Chinese scholars [74]h a v em a d eg o o ds t u d y
and publish the paper on the well-famous journal.
Proteomics technology has been successfully applied
to platelet research, contributing to the emerging ﬁeld of
platelet proteomics which led to the identiﬁcation of a con-
siderable amount of novel platelet proteins, many of which
have been further studied at functional level [76]. During
the last 3 years, a rapid development of two-dimensional
gel electrophoresis and mass spectrometry-based proteomic
approaches has been used to proﬁle alterations in platelet
proteins [77–79]. Using diﬀerential proteomics of platelet,
our previous studies found many diﬀerent platelet proteins
[37, 80] between CHD patients of blood stasis syndrome
(BSS) and non-BSS patients, and healthy controls, which
indicate that the platelet cytoskeleton may play an impor-
tant role in the development in BSS of CHD. Based on6 Evidence-Based Complementary and Alternative Medicine
the Chinese medicine principle of “prescription and syn-
drome are corresponding”, these platelet diﬀerential proteins
maybethenewtargetspotsortargetgroup.Gettingintensive
study on it, we believe that we can develop many new anti-
platelet and antithrombolytic drugs possess deﬁnite curative
eﬀect and target, clear mechanism.
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